iShares US Pharma

Viatris Receives FDA Approval for Generic Drug and Acceptance of New Drug Application, Japanese PMDA Accepts Application

Bristol Myers Squibb Plans to Release 2025 Q4 Earnings

Eli Lilly Announces Positive Results for orforglipron Weight Maintenance Trial

Eli Lilly's Olfiglutide Meets Clinical Trial Endpoints

Eli Lilly Submits New Drug Application for Obesity Treatment to FDA

Ransom Advisory Ltd increased holdings in Eli Lilly in Q3

Chesley Taft & Associates LLC reduced stake in Zoetis Inc. by 61.4% in Q3

Eli Lilly reportedly to cut prices of Mounjaro and Zepbound in Canada by over 20% starting December 29

Eli Lilly's blockbuster diabetes drug Tirzepatide included in China's National Reimbursement Drug List (NRDL)

Eli Lilly Initiates Phase III Clinical Trial of Retatrutide for Metabolic-Associated Fatty Liver Disease in China

MrMed announces strategic partnership with Eli Lilly and launches new cold-chain hub in Bengaluru

Eli Lilly lowers prices for best-selling diabetes and weight-loss drugs in Canada

Lilly Announces Phase 3 EMBER-3 Trial Results for Imlunestrant in Breast Cancer Patients

Eli Lilly's partner in China, Innovent, published Phase 3 clinical results for Mazdutide in Type 2 Diabetes in the journal Nature.

FDA Approves Johnson & Johnson's RYBREVANT FASPRO for EGFR-Mutated Non-Small Cell Lung Cancer

Eli Lilly Garners Attention for a "Trio" of Achievements in Alzheimer's, Obesity, and Cancer

Morgan Stanley Maintains Hold Rating on Pfizer, Cuts Target Price to $28

Guggenheim Upgrades Bristol Myers Squibb Stock Rating to Buy

Eli Lilly partners with the 2026 Winter Olympics, sponsors the US team and donates to non-profit organizations for health equity

Jazz Pharma to Hold Investor Webcast on Zanidatamab Phase 3 Trial Results

Mega Fortune

Processa Pharmaceuticals

cbdMD

Agape ATP

VYNE Therapeutics

Andersen

Inspirato

Medline

Creative Global Tech

GCI LIBERTY INC COM USD0.01 SER C SUBS RTS 17/12/2025

BMO Capital Markets upgraded Merck to "outperform" from "market perform," raising the price target to $130, indicating a 32.2% upside. BMO cites Merck's strategic portfolio assembly to counter Keytruda's 2028 exclusivity loss, with new products expected to offset revenue loss. Investors are focusing on upcoming catalysts, with commercial outperformance expected from Enflonsia, Reblozyl, and Welireg. BMO is confident 90% of Keytruda's peak sales can be replaced by mid-2030s.

Reuters

Merck

BUZZ-BMO upgrades Merck to 'outperform' on multiple upcoming catalysts

Eli Lilly and Company has submitted a new drug application to the U.S. FDA for orforglipron, an investigational, once-daily oral GLP-1 receptor agonist, for treating adults with obesity or overweight. Orforglipron was also granted a Commissioner’s National Priority Voucher from the FDA. This news was originally published by Eli Lilly and Company via PR Newswire on December 18, 2025.

Eli Lilly

Eli Lilly Submits Orforglipron for FDA Review for Obesity Treatment

Ransom Advisory Ltd increased its holdings in Eli Lilly and Company by 112.9% in Q3, owning 2,451 shares worth $1,870,000. Analysts have given Eli Lilly a strong buy rating, with an average target price of $1,141.73. The stock opened at $1,042.06, with a market cap of $985.14 billion. Eli Lilly reported Q3 earnings of $7.02 EPS, beating estimates, and increased its dividend to $1.73 per share.

Market Beat

Ransom Advisory Ltd Increases Stock Position in Eli Lilly and Company $LLY

Chesley Taft & Associates LLC reduced its stake in Zoetis Inc. by 61.4% in Q3. Zoetis shares opened at $122.42, with a 52-week range of $115.25-$177.40. Analysts have issued mixed ratings, with a consensus price target of $161.55. Zoetis reported Q3 EPS of $1.70, beating estimates, and increased its dividend to $0.53 per share.

Zoetis

Chesley Taft & Associates LLC Trims Stock Holdings in Zoetis Inc. $ZTS

The U.S. House passed a Republican healthcare bill, ending ACA subsidies, with a 216-211 vote. The bill aims to lower premiums for some while raising costs for others, expanding access to association health plans. Democrats warn of higher costs and coverage losses, criticizing the bill as a "right-wing health care sham." Speaker Mike Johnson supports the bill, emphasizing a 'patients first' approach.

benzinga_article

Unitedhealth

Johnson & Johnson

House Passes Republican Healthcare Bill Ending ACA Subsidy As Mike Johnson Touts 'Patients First' Approach

Representative Gilbert Ray Cisneros, Jr. (D-California) purchased shares of Merck & Co., Inc. (NYSE:MRK) valued between $1,001 and $15,000 on November 18th, as disclosed in a December 15th filing. The transaction was made through the "150 MAIN STREET TRUST > BANK OF AMERICA" account. Additionally, Cisneros engaged in various other stock transactions, including sales and purchases of companies like Spotify, Alphabet, and LandBridge.

Merck & Co., Inc. (NYSE:MRK) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Dec 17 (Reuters) - Eli Lilly ( LLY ) is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada, the Globe and Mail reported on Wednesday. Reuters could not immediately verify the report. (Reporting by Anusha Shah in Bengaluru; Editing by Mrigank Dhaniwala)

fidelity

Eli Lilly slashes price of diabetes and weight-loss drugs in Canada, Globe and Mail reports

Eli Lilly announced positive results from its Phase 3 ATTAIN-MAINTAIN trial, where orforglipron, an oral GLP-1 receptor agonist, helped maintain weight loss in participants who switched from injectable therapies like Wegovy and Zepbound. The trial met all primary and secondary endpoints, showing superior weight maintenance compared to placebo. Lilly has submitted orforglipron to the FDA for obesity treatment approval. The drug offers a convenient oral alternative for long-term weight management.

StockTitan

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial | LLY Stock News

Novo Nordisk and Eli Lilly have agreed to lower the prices of their GLP-1 weight-loss drugs for Medicare and Medicaid programs, along with cash-paying patients.1Novo Nordisk has committed to the U.S. government's most-favored-nation pricing terms for its drugs, aligning with four other pharmaceutical companies in this agreement.2

TradingView

Novo Nordisk AS

Key facts: Novo Nordisk, Eli Lilly to Cut GLP-1 Drug Prices; Novo Commits to Terms

The FDA has approved Johnson & Johnson's RYBREVANT FASPRO, the first subcutaneous therapy for EGFR-mutated non-small cell lung cancer. This new administration method offers significant advantages in patient convenience and healthcare efficiency, reducing administration time to five minutes and lowering the incidence of administration-related reactions and venous thromboembolism compared to intravenous delivery.

rttnews

FDA Approves Johnson & Johnson's RYBREVANT FASPRO, First Subcutaneous Therapy For EGFR-Mutated NSCLC

Johnson & Johnson's Rybrevant Faspro received FDA approval for treating epidermal growth factor receptor-mutated non-small cell lung cancer. The approval is based on successful Phase 3 trial results, showing improved survival rates and response duration. Rybrevant Faspro offers a simpler administration when combined with Lazcluze, and is approved for four indications in the U.S.

marketscreener

Johnson & Johnson Gets FDA Approval for Lung Cancer Treatment

The ulcerative colitis market is set for significant growth from 2025 to 2034, driven by rising disease prevalence, better diagnosis rates, and the adoption of advanced biologics and novel therapies. Key players like Abivax, Merck, Roche, and Eli Lilly are developing promising treatments. The US leads in market size and diagnosed cases. Despite advancements, a fully safe and curative option remains elusive, highlighting the need for new therapeutic strategies.

prnewswire

17:31 ET
			
			
				Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight

Morgan Stanley has maintained its Hold (Equal-Weight) rating on Pfizer Inc (PFE) while lowering the price target to $28. Pfizer is highlighted as one of the most undervalued pharmaceutical stocks.

- The article discusses a list of the 9 Most Undervalued Pharma Stocks to buy, highlighting Pfizer Inc as the top choice. 
- On December 12, 2025, The Fly reported that Morgan Stanley maintained a Hold (Equal-Weight) rating on Pfizer, while lowering its price target to $28. 
- This indicates a cautious stance towards the stock despite its classification as undervalued.

Pfizer

Pfizer Inc (PFE) rating steady amid neutral market outlook and pipeline progress